{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:39:18Z","timestamp":1763663958216},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n            <jats:title>ABSTRACT<\/jats:title>\n            <jats:p>Many drugs used in medical therapeutics are able to save human lives. Unfortunately, many such drugs have also led to the death of patients. This fact raises important issues discussed in light of a number of cases taken from cardiovascular therapeutics. Medical therapeutics currently includes a vast number of different types of interventions, including drugs, devices, surgery, and diets. In what regards drugs, we currently use molecules with profound influences on the human body\u2014some of which leading occasionally to negative outcomes or even to patient death. A reasonable degree of statistical certainty goes along with a large degree of individual uncertainty\u2014a phenomenon is seen in a group of patients but a quite different phenomenon may be seen in a particular case. When treating an individual patient, it is his\/her interest and personal preferences that must be taken into consideration, not the interests of society or of science. The choice of medical therapy with a definite intrinsic mortality risk must imply strict accordance from the part of the patient. Since many therapeutic modalities do carry a definite mortality risk, an overall change in medical practice is necessary. Informed consent should be the rule, and should be the starting point for medical therapeutics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/j.pbj.0000000000000035","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T11:14:38Z","timestamp":1555154078000},"page":"e35","source":"Crossref","is-referenced-by-count":3,"title":["Medical therapeutics: mortality effects, uncertainty, and informed consent"],"prefix":"10.1097","volume":"4","author":[{"given":"Jos\u00e9 Pedro L.","family":"Nunes","sequence":"first","affiliation":[]}],"member":"276","reference":[{"key":"R1-20230824","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1353\/pbm.2013.0036","article-title":"Medical therapeutics: from induction to scientific evolution","volume":"56","author":"Nunes","year":"2013","journal-title":"Perspect Biol Med."},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bmj.2.4582.769","article-title":"Streptomycin treatment of pulmonary tuberculosis. A medical research council investigation","volume":"2","year":"1948","journal-title":"BMJ."},{"key":"R3-20230824","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1056\/NEJMoa041489","article-title":"Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction","volume":"351","author":"Hohnloser","year":"2004","journal-title":"N Engl J Med."},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet."},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","article-title":"Effects of aspirin for primary prevention in persons with diabetes mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med."},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med."},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa1800722","article-title":"Effect of aspirin on disability-free survival in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med."},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(18)31924-X","article-title":"Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial","volume":"392","author":"Gaziano","year":"2018","journal-title":"Lancet."},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med."},{"key":"R10-20230824","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med."},{"key":"R11-20230824","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0140-6736(08)60601-7","article-title":"Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial","volume":"371","author":"Group","year":"2008","journal-title":"Lancet."},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators","volume":"40","year":"1978","journal-title":"Br Heart J."},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0036933016681913","article-title":"Statins and the cholesterol mortality paradox","volume":"62","author":"Nunes","year":"2017","journal-title":"Scott Med J."},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med."},{"key":"R16-20230824","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med."},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med."},{"key":"R18-20230824","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM199512143332401","article-title":"Tissue plasminogen activator for acute ischemic stroke","volume":"333","year":"1995","journal-title":"N Engl J Med."},{"key":"R19-20230824","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/S0140-6736(16)00163-X","article-title":"Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials","volume":"387","author":"Goyal","year":"2016","journal-title":"Lancet."},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1056\/NEJM196606162742405","article-title":"Ethics and Clinical Research","volume":"274","author":"Beecher","year":"1966","journal-title":"N Engl J Med."},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/bmj.310.6983.827","article-title":"Prophylactic aspirin and risk of peptic ulcer bleeding","volume":"310","author":"Weil","year":"1995","journal-title":"BMJ."}],"container-title":["Porto Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/02054639-201904000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T01:57:06Z","timestamp":1692842226000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/02054639-201904000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/j.pbj.0000000000000035","relation":{},"ISSN":["2444-8664"],"issn-type":[{"value":"2444-8664","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}